Thonzylamine Hydrochloride/Tritoqualine
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Simple Question... Histamine
A simple question... How was histamine discovered ? • by chemical synthesis … • from the analysis of plant extracts (ergot fungus Claviceps purpurea) • from the analysis of animal tissues extracts • through none of these approaches Antihistamines 21/03/2010 1 Histamine ... obtained by synthetic chemist in 1907 …as a chemical curiosity … detection of an identical compound in an extract from ergot fungus … and shown to cause a marked vasodilatation a similar effect is seen with tissues extracts produces a similar picture as a very severe allergic reaction recognized as a "biological" molecule (and not a product from putrefaction in 1927 ... Antihistamines 21/03/2010 2 1 From histidine to histamine ... HN HN CH CH NH 2 2 CH2 CH2 NH2 N COOH N L-histidine decarboxylase First inhibitor tritoqualine of histmine action … commercialized in France (HYPOSTAMINE ) Antihistamines 21/03/2010 3 Localization of histamine total blood leucocytes mastocytes 1. blood plasma other leucocytes 2. tissues ... the word comes from ("histos" = tissue !!) • skin • lung • gastrointestinal tract • central nervous system Antihistamines 21/03/2010 4 2 Actions of histamine • of capillary permability and vasodilatation cutaneous rednesses signs inflammation • bronchoconstriction important with the guinea-pig but under H2 retrocontol in man • of HCl secretion (pariteal cells of the stomach) • neurotransmission awakening reactions, tachycardia, hypertension nauseas, vomitting migraines neurological and comportmental signs Antihistamines 21/03/2010 5 Rappel: -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82 -
United States Patent [191 [11] Patent Number: 5,696,273 Andre Et A]
USOO5696273A United States Patent [191 [11] Patent Number: 5,696,273 Andre et a]. [45] Date of Patent: Dec. 9, 1997 [54] METHOD FOR SYNTHESIZING OTHER PUBLICATIONS CUCURBITINE Pn'ce. Pathophysiology. Clinical Concepts of Disease Pro [75] Inventors: Patrice Andre. Neuvilles aux Bois; cess~ 19,36~ PP- 36-37- ‘ _ valérie Thiery_ Clery St Andre; Gémld Webster s New World Dictionary. 1988. p. 36. Guillaumet‘ 01-16mm an of France World Patents Index Latest. AN 87-32998? [47]. Derwent Publications Ltd.. London. GB. & JP. S. 62234013 (Osaka [73] Assignee: Parfums Christian Dior. Paris. France Yak'lhin Kmky) 14 Oct- 1937 Chemical Abstract. vol. 82. No. 23. 1975. p. 40. abstract _ 149446a. Pharmacological (anthelminthic) study of Cucur [21] APPL N°" 476’646 bita. ,A.E. Gonzalez a a1. [22] Filed; Jm 7, 1995 Scienta Sinica. vol. X. No. 7. 1961.T.-T. Sun et a1. “Chemi cal studies on cucurbita moschata duch". pp. 852-859. Related US. Application Data Journal of the Chemical Society. Chemical Communica tions. 1973. H]. Monteiro, “New synthesis of the ami [62] Division of Ser. No. 108,601 , ?led as PCT/FR92/00164 Feb. no-acid (+)-Cucurbitine”. p. 2. 24’ 1992, abandmed- Chemical and Pharmaceutical Bulletin. vol. 35. No. 9. Sep. [30] Foreign. Application. Pl'lol'lty. Data ..'. 5183;135:2149?' t.‘ nzym esandcatalsts.H.Pi y g Feb. 28, 1991 [FR] France ................................. .. 9102420 J. Fable. “Methoden der Organischen Chemie". vol. E5. Georg Thieme Verlag pp. 534-543. (1973). [5 .................... .. C071) 207/36 Derwent Publications Ltd. 52051033AN (Ogawa) 23 Apr.& 1977. [52] US. Cl. 548/531; 548/542; 548/550 world Patents Indcx Latest, 1937‘ AN 37473336 [39]_ [58] Field of Search 5481531. -
Prohibited Substances List
Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). -
(19) United States (12) Patent Application Publication (10) Pub
US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine. -
Selective Reaction Monitoring (SRM) Daten Von Mehr Als 900 Xenobiotika Für Aufbau Und Validierung Von LC-MS/MS Analysen
T + K (2008) 75 (3): 149 Selective Reaction Monitoring (SRM) Daten von mehr als 900 Xenobiotika für Aufbau und Validierung von LC-MS/MS Analysen Brunhilde Güssregen, Stefanie Schröfel, Markus Nauck, Torsten Arndt Bioscientia Institut für Medizinische Diagnostik GmbH, Konrad-Adenauer-Str. 17, 55218 Ingelheim; e-mail: [email protected] Die Flüssigkeitschromatographie-Tandem-Massenspektrometrie (LC-MS/MS) hat in den letz- ten Jahren eine zunehmende Bedeutung nicht nur in der klinisch-chemischen sondern auch in der toxikologischen Analytik gewonnen. Sie kann heute neben den klassischen Verfahren wie UV/VIS-Spektrometrie, Hochleistungs-Flüssigkeitschromatographie (HPLC) und Gaschro- matographie-Massenspektrometrie (GC-MS) als integraler Bestandteil der qualitativen und quantitativen Analytik gewertet werden. Dies drückt sich nicht zuletzt in der steigenden Zahl der Meldungen von mit LC-MS/MS erhobenen GTFCh- Ringversuchsergebnissen aus. Die Ursachen für diese Popularität sind vielfältig. Es sind u. a. einige analytische Vorteile im Vergleich zu den o. g. Analysentechniken: Vereinfachte Probenvorbereitung (z. B. ohne Derivatisierungsreaktionen), Einsatz geringerer Probenmengen, Kürzere Chromatographie- und dadurch Analysezeiten, Spezifitätssteigerung durch die Kombination von minimal 4 Identifizierungskriterien (Retentionszeit, Massenübergänge 1 und 2 [SRM 1 und SRM 2], Intensitätsverhältnis von SRM1 und SRM2), deren Anzahl bei Verwendung von mehr als 2 SRM erhöht werden kann, Eignung für alle löslichen Substanzen unabhängig von ihrer Fähigkeit, zerstörungs- frei in die Gasphase überführt werden zu können. Derzeitige Nachteile der LC-MS/MS im Methodenvergleich sind: Fehlende Standardisierung sowohl der Chromatographie- als auch der Tandem-Mas- senspektrometrie-Analysenteilschritte, Variabilität der Massenspektren infolge der vglw. milden Fragmentierungsbedingun- gen, Fehlen von allgemein verfügbaren LC-MS/MS-Spektren- und/oder Massenübergangs (SRM)-Bibliotheken mit einer der Pfleger-Maurer-Weber Bibliothek [1] oder der Pragst et al. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
236 Subpart A—General Provisions Subpart B—Active Ingredients
§ 341.1 21 CFR Ch. I (4–1–01 Edition) 341.78 Labeling of expectorant drug prod- (g) Topical nasal decongestant drug. A ucts. drug that when applied topically inside 341.80 Labeling of nasal decongestant drug the nose, in the form of drops, jellies, products. or sprays, or when inhaled intranasally 341.90 Professional labeling. reduces nasal congestion caused by AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, acute or chronic rhinitis. 360, 371. (h) Calibrated dropper. A dropper cali- brated such that the volume error in- Subpart A—General Provisions curred in measuring any liquid does not exceed 15 percent under normal use § 341.1 Scope. conditions. (a) An over-the-counter cold, cough, [51 FR 35339, Oct. 2, 1986, as amended at 54 FR allergy, bronchodilator, or anti- 8509, Feb. 28, 1989; 55 FR 40382, Oct. 3, 1990; 57 asthmatic drug product in a form suit- FR 58374, Dec. 9, 1992; 59 FR 43409, Aug. 23, able for oral, inhalant, or topical ad- 1994] ministration is generally recognized as safe and effective and is not mis- Subpart B—Active Ingredients branded if it meets each of the condi- tions in this part and each of the gen- § 341.12 Antihistamine active ingredi- eral conditions established in § 330.1. ents. (b) References in this part to regu- The active ingredient of the product latory sections of the Code of Federal consists of any of the following when Regulations are to chapter I of title 21 used within the dosage limits estab- unless otherwise noted. lished for each ingredient: [51 FR 35339, Oct. -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)
Proposed changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (effective from 01.01.2022) SUBSTANCE NAME CURRENT PROPOSED COMMENT STATUS EPSL CATEGORY ACETYLCHOLINESTERASE INHIBITOR Used in the treatment of Edrophonium Controlled Banned myasthenia gravis and Medication Substance has no legitimate use in the treatment of sports horses Used to increase Huperzine A Unlisted Banned alertness and treat Substance myasthenia gravis. The substance has no legitimate use in the treatment of sports horses. AMIDES Palmitoylethanolamid Banned Controlled Used in the treatment of Substance Medication joint pain ANGIOTENSIN CONVERTING ENZYME INHIBITORS Enalapril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Enalaprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Lisinopril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Moexipril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse 1 Perindoprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse ANTIHISTAMINES Antazoline Controlled Banned The substance has no Medication Substance legitimate use in the sports horse Azatadine Controlled Banned The substance has Medication Substance sedative effects -
APO-Glimepiride 1 Mg Tablets: Educator Will Show You How and When to Do This
APO-Glimepiride Contains the active ingredient glimepiride Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 Ask your doctor if you have any questions Talk to your doctor or pharmacist if you are 195 055 about why this medicine has been prescribed not sure whether you should start taking this for you. medicine. What is in this leaflet This medicine is available only with a doctor's Before you start to take it prescription. Tell your doctor if: This leaflet answers some common questions There is no evidence that this medicine is about APO-Glimepiride. It does not contain all of addictive. 1. You have allergies to: the available information. - any other medicines - lactose It does not take the place of talking to your doctor Before you take this medicine or pharmacist. - any other substances such as food, preservatives, or dyes All medicines have risks and benefits. Your When you must not take it 2. You have or have had any medical doctor has weighed the risks of you taking this Do not take this medicine if you have had an conditions, especially the following: medicine against the benefits this medicine is allergic reaction to: expected to have for you. - liver problems • glimepiride or other sulfonylureas - kidney problems Ask your doctor or pharmacist if you have any • antibiotics called sulphonamides - a deficiency in the enzyme in your body concerns about taking this medicine. • thiazide diuretics (a type of fluid or water called glucose-6-phosphate dehydrogenase Keep this leaflet with the medicine. tablets) (G6PD) You may need to read it again. -
Marrakesh Agreement Establishing the World Trade Organization
No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX